Both Pfizer and Merck are scheduled to release their most recent quarterly results before the markets open on Tuesday. These are the two biggest companies in the pharma industry and they can…
24/7 Wall St. has put together a preview of Apple, McDonald's, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Monday include Amazon.com, Caterpillar, Exxon Mobil, Honeywell, Lululemon Athletica, Merck, Petrobras and Under Armour.
The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, National Oilwell Varco, Netflix and Twitter.
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall…
UnitedHealth, Merck, Verizon, and Caterpillar led the Dow to a nice gain Monday.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.
Chris Lange Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Merck and Walmart were among Wednesday's biggest gainers on the Dow while Intel and Cisco were among the big losers.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The Stifel view is that it is time for investors to take a more defensive posture, but that doesn’t mean selling everything and going to cash.
